Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review

Pitton Rissardo, Jamir; Fornari Caprara, Ana Letícia

doi:10.3390/brainsci13101471

Cited by 15 publications

(6 citation statements)

References 193 publications

(171 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DaTscan can help differentiate between Parkinson's disease and other causes of parkinsonism, including drug-induced parkinsonism. In some cases, using I123-cardiac MIBG can help distinguish between secondary and primary parkinsonism [122].…”

Section: Imaging Studiesmentioning

confidence: 99%

Understanding Drug-Induced Movement Disorders: Causes, Symptoms, and Treatment

R. Santos

2024

Preprint

View full text Add to dashboard Cite

Drug-induced movement disorders (DIMDs) are a group of neurological conditions caused by the use of certain medications. These disorders can significantly impact a person's quality of life and are essential to recognize and manage. This article provides an overview of the causes, symptoms, and treatment of DIMDs. DIMDs can manifest in various forms, including parkinsonism, tardive dyskinesia, dystonia, and akathisia. They are most commonly associated with medications such as neuroleptics, antidepressants, antipsychotics, antiemetics, and anticonvulsants. Risk factors for developing DIMDs include age, genetics, duration of medication use, and dose of medication. Symptoms of DIMDs can range from mild to severe and may include tremors, rigidity, bradykinesia, and involuntary movements. These symptoms can significantly impact a person's ability to perform daily activities and lead to social isolation and decreased quality of life. DIMD diagnoses are based on clinical evaluation, including a thorough medical history and physical examination. Imaging studies such as MRI or CT scans may also be used to rule out other possible causes of symptoms. Treatment of DIMDs involves the withdrawal of the offending medication if possible. Pharmacological treatments such as anticholinergic drugs, benzodiazepines, and dopamine agonists may also be used to manage symptoms. Non-pharmacological treatments such as physical, occupational, and speech therapy can also be beneficial. DIMDs are necessary neurological conditions that can significantly impact a person's quality of life. Early recognition and management of these disorders are essential for optimizing outcomes. Further research is needed to understand the underlying mechanisms of DIMDs better and to develop more effective treatments.

show abstract

Section: Imaging Studiesmentioning

confidence: 99%

Understanding Drug-Induced Movement Disorders: Causes, Symptoms, and Treatment

R. Santos

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…In drug-induced parkinsonism, a reduction in dopamine transporter binding may be observed, and this reduction is reversible upon discontinuation of the offending medication. Neuroimaging findings should be interpreted in conjunction with the clinical presentation and history of medication use [199]. A clear temporal relationship between the initiation of a specific drug and the onset of parkinsonian symptoms can strengthen the suspicion of drug-induced parkinsonism.…”

Section: Neuroimaging In Drug-induced Parkinsonismmentioning

confidence: 99%

A Literature Review of Movement Disorder Associated with Medications and Systemic Diseases

Pitton Rissardo,

Fornari Caprara

2024

Preprint

View full text Add to dashboard Cite

Movement disorders can be associated with various drugs and systemic diseases, posing diagnostic challenges for clinicians. This review explores the spectrum of movement disorders associated with pharmacological agents and medical conditions. Drug-induced movement disorders encompass a broad range of conditions resulting from exposure to medications that affect several neurotransmitters. Neuroleptic medications can lead to tardive dyskinesia, characterized by involuntary, repetitive movements. Antipsychotics and antiemetics, including metoclopramide, may induce acute dystonic reactions. Other drugs, such as dopamine receptor-blocking agents, can contribute to drug-induced parkinsonism. Beyond medications, movement disorders can also arise secondary to systemic diseases. Metabolic disorders like Wilson's disease, characterized by copper accumulation, may manifest as chorea or dystonia. Inflammatory conditions such as rheumatoid arthritis and systemic lupus erythematosus can result in secondary movement disorders due to autoimmune-mediated processes affecting the central nervous system. Movement disorders linked to drugs or systemic diseases often necessitate a thorough clinical evaluation, including detailed medication histories and comprehensive systemic assessments. Neuroimaging, laboratory investigations, and, in some cases, cerebrospinal fluid analyses and electrodiagnostic studies help in establishing accurate diagnoses. Management involves addressing the underlying cause, modifying medications, and employing symptomatic treatments.

show abstract

“…SPECT imaging is advantageous in assessing changes in brain perfusion in conditions such as Huntington's disease and other neurodegenerative disorders. Cardiac 123Imetaiodobenzylguanidine (MIBG) scintigraphy has already proven helpful in supporting the diagnosis of Parkinson's disease [118].…”

Section: Neuroimagingmentioning

confidence: 99%

Advances in Understanding and Managing Movement Disorders: A Comprehensive Review

R. Santos

2024

Preprint

View full text Add to dashboard Cite

Movement disorders encompass a diverse group of neurological conditions characterized by abnormal voluntary or involuntary movements. These disorders can be classified broadly into hyperkinetic and hypokinetic disorders. Excessive, involuntary movements, including tremors, dystonia, chorea, and myoclonus characterize hyperkinetic disorders. Tremors are rhythmic, involuntary movements occurring at rest or during movement. Dystonia involves sustained muscle contractions, leading to twisting and repetitive movements or abnormal postures. Chorea manifests as brief, irregular, involuntary movements that flow from one body part to another. Myoclonus consists of sudden, brief muscle contractions, either spontaneous or in response to a stimulus. Hypokinetic disorders are characterized by a lack of movement or difficulty initiating movement, as seen in Parkinson's disease and Parkinsonism. Parkinson's disease is a progressive neurological disorder that primarily affects movement, causing tremors, stiffness, and difficulty with balance and coordination. Parkinsonism refers to a group of disorders with similar symptoms to Parkinson's disease but with different underlying causes. Diagnosing movement disorders involves a thorough clinical evaluation, including a detailed medical history and physical examination. Neuroimaging studies such as MRI, CT scans, and functional imaging techniques may be used to assess brain structure and function. Additionally, laboratory tests, including genetic testing and biochemical markers, can help diagnose certain movement disorders.

show abstract

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review

Cited by 15 publications

References 193 publications

Understanding Drug-Induced Movement Disorders: Causes, Symptoms, and Treatment

Understanding Drug-Induced Movement Disorders: Causes, Symptoms, and Treatment

A Literature Review of Movement Disorder Associated with Medications and Systemic Diseases

Advances in Understanding and Managing Movement Disorders: A Comprehensive Review

Contact Info

Product

Resources

About